1
|
Croci S, Manicardi A, Rubagotti S, Bonacini M, Iori M, Capponi PC, Cicoria G, Parmeggiani M, Salvarani C, Versari A, Corradini R, Asti M. 64Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Sci Rep 2019; 9:3376. [PMID: 30833583 PMCID: PMC6399270 DOI: 10.1038/s41598-018-35800-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 11/08/2018] [Indexed: 01/23/2023] Open
Abstract
MiRNAs are single stranded RNAs of 18–22 nucleotides. They are promising diagnostic and prognostic markers for several pathologies including tumors, neurodegenerative, cardiovascular and autoimmune diseases. In the present work the development and characterization of anti-miRNA radiolabeled probes based on peptide nucleic acids (PNAs) for potential non-invasive molecular imaging in vivo of giant cell arteritis are described. MiR-146a and miR-146b-5p were selected as targets because they have been found up-regulated in this disease. Anti-miR and scramble PNAs were synthesized and linked to carboxyfluorescein or DOTA. DOTA-anti-miR PNAs were then labelled with copper-64 (64Cu) to function as non-invasive molecular imaging tools. The affinity of the probes for the targets was assessed in vitro by circular dichroism and melting temperature. Differential uptake of fluorescein and 64Cu labeled anti-miRNA probes was tested on BCPAP and A549 cell lines, expressing different levels of miR-146a and -146b-5p. The experiments showed that the anti-miR-146a PNAs were more effective than the anti-miR-146b-5p PNAs. Anti-miR-146a PNAs could bind both miR-146a and miR-146b-5p. The uptake of fluorescein and 64Cu labeled anti-miR-146a PNAs was higher than that of the negative control scramble PNAs in miRNA expressing cells in vitro. 64Cu-anti-miR-146a PNAs might be further investigated for non-invasive PET imaging of miR-146 overexpressing diseases.
Collapse
Affiliation(s)
- Stefania Croci
- Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Alex Manicardi
- Department of Chemistry, Live Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze, Parma, 43124, Italy.,Organic and Biomimetic Chemistry Research Group, Department of Organic Chemistry, Faculty of Science, Ghent University, Krijgslaan 281-S4, Gent, 9000, Belgium
| | - Sara Rubagotti
- Nuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Martina Bonacini
- Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Michele Iori
- Nuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Pier Cesare Capponi
- Nuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Gianfranco Cicoria
- Medical Physics Department, University Hospital "S. Orsola-Malpighi", 40138, Bologna, Italy
| | - Maria Parmeggiani
- Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Carlo Salvarani
- Rheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.,Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Annibale Versari
- Nuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy
| | - Roberto Corradini
- Department of Chemistry, Live Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze, Parma, 43124, Italy
| | - Mattia Asti
- Nuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
| |
Collapse
|
2
|
Patel PL, Rana NK, Patel MR, Kozuch SD, Sabatino D. Nucleic Acid Bioconjugates in Cancer Detection and Therapy. ChemMedChem 2015; 11:252-69. [PMID: 26663095 DOI: 10.1002/cmdc.201500502] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Revised: 11/23/2015] [Indexed: 12/28/2022]
Abstract
Nucleoside- and nucleotide-based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive nucleic acid component is improved by conjugation with delivery vectors, small-molecule drugs, and/or imaging modalities. In this manner, nucleic acid bioconjugates have the potential for targeting and effecting multiple biological processes in tumors, leading to synergistic antitumor effects. Consequently, tumor resistance and recurrence is mitigated, leading to more effective forms of cancer therapy. Bioorthogonal chemistry has led to the development of new nucleoside bioconjugates, which have served to improve treatment efficacy en route towards FDA approval. Similarly, oligonucleotide bioconjugates have shown encouraging preclinical and clinical results. The modified oligonucleotides and their pharmaceutically active formulations have addressed many weaknesses of oligonucleotide-based drugs. They have also paved the way for important advancements in cancer diagnosis and treatment. Cancer-targeting ligands such as small-molecules, peptides, and monoclonal antibody fragments have all been successfully applied in oligonucleotide bioconjugation and have shown promising anticancer effects in vitro and in vivo. Thus, the application of bioorthogonal chemistry will, in all likelihood, continue to supply a promising pipeline of nucleic acid bioconjugates for applications in cancer detection and therapy.
Collapse
Affiliation(s)
- Pradeepkumar L Patel
- Sun Pharmaceutical Industries Inc., Analytical Research and Development, 270 Prospect Plains Road, Cranbury, NJ, 08512, USA
| | - Niki K Rana
- Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, NJ, 07079, USA
| | - Mayurbhai R Patel
- Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, NJ, 07079, USA
| | - Stephen D Kozuch
- Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, NJ, 07079, USA
| | - David Sabatino
- Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, NJ, 07079, USA.
| |
Collapse
|